Solid Tumors Clinical Trial
Official title:
A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types
Mesenchymal epithelial transition factor (c-MET) is a receptor tyrosine kinase that, when
engaged by its ligand hepatocyte growth factor (HGF), has been implicated in various cellular
process including development as well as oncogenesis.
SAIT301 is a novel humanized monoclonal antibody targeting the alpha chain of extracellular
domain of c-MET. Binding of SAIT301 to c-MET blocks HGF binding and inhibits HGF-mediated
signaling. Furthermore, SAIT301 also induces efficient c-MET internalization from the cell
surface and subsequent degradation, resulting in inhibition of growth of the c-MET addicted
cancer cells.
The sponsor decided to enroll subjects with tumors that express c-MET (by
immunohistochemistry [IHC]) for this study, as the subjects with no c-MET expression are
unlikely to benefit from SAIT301 treatment.
Stage 1 of this Phase I study is designed to evaluate the safety, tolerability,
pharmacokinetic (PK) profile, and anti-tumor activity of SAIT301 administered as a single IV
infusion in 21 day cycles, for up to 4 cycles. Subjects without evidence of tumor progression
after 4 cycles will be eligible to continue on SAIT301 treatment if there is no evidence of
tumor progression for a further 4 cycles (Cycles 5 to 8). Biomarkers related to SAIT301
and/or tumor response will also be evaluated.Stage 2 will further evaluate the safety and PK
profile of SAIT301 in select types of cancers. Dosing frequency may be adjusted based on the
PK profile obtained during Stage 1.
The primary objectives of the study are as follows:
- To evaluate the safety and tolerability of SAIT301.
- To determine the MTD of SAIT301 and the dose level of SAIT301 where dose limiting
toxicity (DLT) is observed in subjects with advanced solid tumors or define recommended
Phase II dose (RP2D) as an alternative to establishing the MTD.
Methodology: This first in man study will consist of 2 stages. Stage 1 will be a dose
escalation study with a 3 + 3 design and will evaluate the safety, tolerability, PK profile,
biomarkers, and preliminary anti-tumor activity of ascending doses of SAIT301 in subjects
with c-MET + advanced solid tumors and define the MTD (or recommended Phase II dose [RP2D])
of SAIT301. If the PK trough levels exceed the minimum acceptable trough level for SAIT301
(25 μg/mL), the Safety Review Committee (SRC) may elect to terminate further dose escalation
and declare a recommended Phase II dose (RP2D) and schedule as an alternative to establishing
the MTD. In Stage 2 the MTD (or RP2D) defined in Stage 1 will be administered to additional
subjects with selected diagnoses, 15 subjects per selected diagnosis, to further evaluate the
safety and PK profile, and any evidence of anti tumor activity of SAIT301 in these
populations. The tumor types to be included in Stage 2 will be defined in a protocol
amendment at a time close to study execution based on information available at that time.
The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be
administered as an intravenous (IV) infusion.
For dose level 1, the first subject will receive an IV infusion of SAIT301 on Cycle 1 Day 1
and will be followed for 21 days (Cycle 1).
If the first subject at dose level 1 experiences a DLT during Cycle 1, 1 additional subject
will be enrolled and will receive dose level 1, which is 50% of dose level 1. If this subject
at dose level -1 does not experience a DLT during Cycle 1, 2 more subjects will be enrolled
at dose level -1.
If the first subject at dose level 1 does not experience a DLT during Cycle 1, the second and
third subjects will receive SAIT301 at dose level 1 and will be followed for 21 days (Cycle
1). At the discretion of the SRC, if the first 3 subjects at dose level 1 do not experience a
DLT during Cycle 1, dose level 2 may be administered in the next cohort. If one of these
subjects experiences a DLT, the cohort will be expanded and evaluated as described below.
For dose level 2 and each subsequent dose level, 3 subjects will receive SAIT301 on Day 1 of
Cycle 1 and will be followed for 21 days (Cycle 1). If none of the 3 subjects experience a
DLT, the next dose level can be administered in the next cohort. If 1 or more of the first 3
subjects experience a DLT, 3 more subjects will receive the same dose level. Dose escalation
will continue until at least 2 subjects in a cohort of 3 to 6 subjects experience a DLT
(i.e., ≥33% of subjects with a DLT at that dose level). Considering the possibility of
relatively low efficacy, each subjects of dose level 1 and 2 can be administered with higher
dose level after their first administration. This individual dose escalation can be
determined by Investigators when safety data of the higher dose level are available.
For both Stage 1 and 2, subjects will continue to receive the assigned dose level of SAIT301
until unacceptable toxicity, documented progression of disease, another criterion for
discontinuation is met, or until 4 cycles have been completed.
Subjects without evidence of tumor progression after 4 cycles may continue on SAIT301
treatment if there is no evidence of tumor progression for a further 4 cycles (Cycles 5 to
8). Subjects without evidence of tumor progression at the completion of Cycle 8 will be
eligible for a follow-on protocol.
Subjects who experience a DLT will be discontinued from further treatment. At the completion
of the dose escalation stage, the SRC may for Stage 2 alter the dosing interval between
cycles based on emerging PK data from lower SAIT301 dose levels.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |